MDM2 Polymorphism, Survival, and Histology in Early-Stage Non–Small-Cell Lung Cancer
- 1 June 2007
- journal article
- thoracic oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (16), 2243-2247
- https://doi.org/10.1200/jco.2006.08.8914
Abstract
MDM2 is a negative regulator of p53. The MDM2 309T/G polymorphism has been associated with differential MDM2 expression levels and inhibition of the p53 pathway. We hypothesized that the MDM2 G/G genotype may be associated with worse survival outcomes in lung cancer, especially in squamous cell cancers where p53 abnormalities are more common. We evaluated the relationship between MDM2 polymorphism status and overall survival (OS) among patients with early-stage non–small-cell lung cancer (NSCLC) treated with surgical resection at Massachusetts General Hospital from 1992 to 2000. Kaplan-Meier methods and the log-rank test were used to compare survival by polymorphism status. Cox proportional hazards models were used to adjust for possible confounding variables. There were 383 patients in the analysis. In the early-stage population as a whole, the G/G genotype seemed to be associated with worse OS on adjusted analysis (adjusted hazard ratio = 1.57; 95% CI, 1.03 to 2.40; P = .04). Among patients with squamous histology, OS was significantly worse among those with the G/G genotype (P = .0001 by log-rank test), with 5-year survival rates among the genotypes of 59% for T/T, 53% for T/G, and 7% for G/G. Our findings suggest that the G/G genotype of the MDM2 polymorphism is associated with worse OS among early-stage NSCLC patients, particularly those with squamous cell histology.Keywords
This publication has 22 references indexed in Scilit:
- MDM2 Promoter Polymorphism Is Associated With Both an Increased Susceptibility to Gastric Carcinoma and Poor PrognosisJournal of Clinical Oncology, 2006
- Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patientsLung Cancer, 2006
- MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysisCarcinogenesis: Integrative Cancer Research, 2006
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- Targeting the p53–MDM2 interaction to treat cancerBritish Journal of Cancer, 2004
- MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)Lung Cancer, 2004
- An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and TumorigenesisPublished by Elsevier BV ,2004
- The p53–Mdm2 module and the ubiquitin systemSeminars in Cancer Biology, 2002
- The p53 network in lung carcinogenesisOncogene, 2002
- Patterns of p53 G->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smokeCarcinogenesis: Integrative Cancer Research, 2001